Sprott Inc. Makes New $30,000 Investment in Gain Therapeutics, Inc. (NASDAQ:GANX)

Sprott Inc. purchased a new stake in shares of Gain Therapeutics, Inc. (NASDAQ:GANX) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund purchased 14,000 shares of the company’s stock, valued at approximately $30,000. Sprott Inc. owned 0.05% of Gain Therapeutics at the end of the most recent reporting period.

Separately, Geode Capital Management LLC raised its stake in Gain Therapeutics by 48.0% during the 3rd quarter. Geode Capital Management LLC now owns 271,972 shares of the company’s stock valued at $484,000 after purchasing an additional 88,236 shares during the period. Hedge funds and other institutional investors own 11.97% of the company’s stock.

Gain Therapeutics Price Performance

Shares of NASDAQ:GANX opened at $2.00 on Thursday. The firm has a market cap of $53.05 million, a price-to-earnings ratio of -1.82 and a beta of 0.14. Gain Therapeutics, Inc. has a 1 year low of $0.89 and a 1 year high of $5.19. The company has a current ratio of 2.99, a quick ratio of 2.99 and a debt-to-equity ratio of 0.04. The business has a fifty day simple moving average of $2.20 and a 200 day simple moving average of $1.92.

Analysts Set New Price Targets

Several analysts have recently commented on the company. Roth Mkm reaffirmed a “buy” rating and issued a $7.00 target price on shares of Gain Therapeutics in a research report on Tuesday, December 24th. HC Wainwright restated a “buy” rating and set a $8.00 price objective on shares of Gain Therapeutics in a research report on Monday, November 25th. Finally, Roth Capital upgraded Gain Therapeutics to a “strong-buy” rating in a report on Thursday, December 5th. Four research analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and an average price target of $7.25.

Gain Therapeutics Profile

Gain Therapeutics, Inc, a biotechnology company, develops novel small molecule therapeutics to treat diseases across various therapeutic areas. Its drug discovery platform Magellan discovers novel allosteric binding sites in a disease; identifies proprietary small molecules that bind these sites to modulate protein function; and treats the underlying cause of the disease.